GB Sciences (GBLX) 10-K 6 Jul 21 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Mar. 31, 2021	Jul. 02, 2021	Sep. 30, 2020
Document Information [Line Items]
Entity Registrant Name	GB SCIENCES INC
Entity Central Index Key	0001165320
Current Fiscal Year End Date	--03-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		317,012,411
Entity Public Float			$ 7.4
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(g) Security	Common Stock $.0001 Par Value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Mar. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 793,040	$ 2,406
Prepaid expenses and other current assets	256,251	18,776
Note receivable		5,224,423
Current assets from discontinued operations	2,494,564	1,755,275
TOTAL CURRENT ASSETS	3,543,855	7,000,880
Property and equipment, net	25,022	37,821
Intangible assets, net of accumulated amortization of $43,096 and $12,287 at March 31, 2021 and 2020, respectively	1,706,762	1,128,702
Long term assets from discontinued operations	5,530,415	6,185,465
TOTAL ASSETS	10,806,054	14,352,868
CURRENT LIABILITIES:
Accounts payable	1,412,459	1,913,049
Accrued interest	493,741	366,865
Accrued liabilities	957,946	813,618
Notes and convertible notes payable, net of unamortized discount of $296,504 and $608,580 at March 31, 2021 and 2020, respectively	3,594,804	5,054,728
Indebtedness to related parties	84,913	586,512
Note payable to related party		151,923
Current liabilities from discontinued operations	2,054,585	1,999,062
TOTAL CURRENT LIABILITIES	8,598,448	10,885,757
Convertible notes payable, net of unamortized discount of $154,590 and $0 at March 31, 2021 and 2020, respectively	292,410
Long term liabilities from discontinued operations	3,389,124	3,555,605
TOTAL LIABILITIES	12,279,982	14,441,362
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY/(DEFICIT):
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 315,340,411 and 275,541,602 outstanding at March 31, 2021 and 2020, respectively	31,534	27,554
Additional paid-in capital	102,380,770	97,271,157
Accumulated deficit	(103,886,232)	(97,387,205)
TOTAL STOCKHOLDERS' DEFICIT	(1,473,928)	(88,494)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 10,806,054	$ 14,352,868

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Intangible assets, accumulated amortization	$ 43,096	$ 12,287
Unamortized discount, current	296,504	608,580
Unamortized discount, noncurrent	$ 154,590	$ 0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	315,340,411	275,541,602
Common stock, shares outstanding (in shares)	315,340,411	275,541,602

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Sales revenue
Cost of goods sold
Gross profit (loss)
General and administrative expenses	2,001,617	5,741,514
LOSS FROM OPERATIONS	(2,001,617)	(5,741,514)
OTHER INCOME (EXPENSE)
Gain/(loss) on extinguishment	467,872	(216,954)
Gain on settlement of accounts payable	422,414
Gain on deconsolidation		4,393,242
Interest expense	(1,285,460)	(1,109,031)
Loss on modification of line of credit	650,000
Loss on note receivable modification		1,895,434
Debt default penalty	(286,059)
Other expense		179,368
Total other income/(expense)	(1,331,233)	992,455
LOSS BEFORE INCOME TAXES	(3,332,850)	(4,749,059)
Income tax expense (Note 8)
LOSS FROM CONTINUING OPERATIONS	(3,332,850)	(4,749,059)
Net loss from discontinued operations (Note 4)	(392,177)	(8,362,626)
NET LOSS	(3,725,027)	(13,111,685)
Loss attributable to non-controlling interest		(738,106)
NET LOSS ATTRIBUTABLE TO GB SCIENCES, INC.	(3,725,027)	(12,373,579)
Net loss attributable to common stockholders of GB Sciences, Inc.
Continuing operations	(3,332,850)	(4,749,059)
Discontinued operations	(392,177)	(7,624,520)
Net loss	$ (3,725,027)	$ (12,373,579)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ (0.01)	$ (0.02)
Discontinued operations (in dollars per share)	0	(0.03)
Net loss (in dollars per share)	$ (0.01)	$ (0.05)
Weighted average common shares outstanding - basic and diluted (in shares)	285,190,729	258,450,641

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity/(Deficit) - USD ($)	Cumulative Effect, Period of Adoption, Adjustment [Member]Common Stock [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Additional Paid-in Capital [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Retained Earnings [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]Noncontrolling Interest [Member]	Cumulative Effect, Period of Adoption, Adjustment [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Mar. 31, 2019						240,627,102
Balance (Accounting Standards Update 2016-02 [Member]) at Mar. 31, 2019			$ (7,550)		$ (7,550)
Balance at Mar. 31, 2019						$ 24,063	$ 93,020,015	$ (84,743,836)	$ 8,855,757	$ 17,155,999
Issuance of stock for debt conversion (in shares)						7,583,333
Issuance of stock for debt conversion						$ 758	524,242			$ 525,000
Exercise of warrants for stock, net of issuance costs (in shares)						17,563,000				17,563,000
Exercise of warrants for stock, net of issuance costs						$ 1,756	1,155,971			$ 1,157,727
Issuance of stock for services (in shares)						2,100,000				2,100,000
Issuance of stock for services						$ 210	213,790			$ 214,000
Share based compensation expense							287,260			287,260
Issuance of stock for cash, net of issuance costs (in shares)						7,668,167
Issuance of stock for cash, net of issuance costs						$ 767	717,929			718,696
Beneficial conversion feature on notes payable							829,737			829,737
Contributions from non-controlling interest									590,000	590,000
Compensation warrants							132,914			132,914
Induced Dividend from Warrant Exercises							262,240	(262,240)
Induced conversions of accrued interest on notes payable							127,059			127,059
Deconsolidation of GB Sciences Louisiana, LLC									(8,707,651)	(8,707,651)
Net loss								(12,373,579)		(12,373,579)
Loss attributable to non-controlling interest									(738,106)	(738,106)
Balance (in shares) at Mar. 31, 2020						275,541,602
Balance at Mar. 31, 2020						$ 27,554	97,271,157	(97,387,205)		(88,494)
Issuance of stock for debt conversion (in shares)						4,000,000
Issuance of stock for debt conversion						$ 400	159,600			160,000
Exercise of warrants for stock, net of issuance costs (in shares)						35,798,809
Exercise of warrants for stock, net of issuance costs						$ 3,580	964,443			968,023
Share based compensation expense							436,349			436,349
Beneficial conversion feature on notes payable							543,886			543,886
Compensation warrants							231,335			231,335
Induced Dividend from Warrant Exercises							2,774,000	(2,774,000)
Net loss								(3,725,027)		(3,725,027)
Loss attributable to non-controlling interest
Balance (in shares) at Mar. 31, 2021						315,340,411
Balance at Mar. 31, 2021						$ 31,534	$ 102,380,770	$ (103,886,232)		$ (1,473,928)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
OPERATING ACTIVITIES:
Net loss	$ (3,725,027)	$ (13,111,685)
Loss from discontinued operations	(392,177)	(8,362,626)
Net loss from continuing operations	(3,332,850)	(4,749,059)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	47,353	125,502
Stock-based compensation	436,349	287,260
Stock issued for services		214,000
Compensation warrants	231,335	132,914
Amortization of debt discount and beneficial conversion feature	776,122	1,150,995
Debt default penalty	286,059
Interest expense on conversion of notes payable		84,354
Loss on modification of line of credit	650,000
Loss/(gain) on extinguishment	(467,872)	216,954
Gain on settlement of accounts payable	(422,414)
Loss on disposal of assets and termination of operating lease		147,953
Loss on induced conversion of note payable		127,059
Loss on note receivable modification		1,895,434
Gain on deconsolidation		(4,393,242)
Interest income receivable and amortization of discount on note receivable		(509,265)
Changes in operating assets and liabilities:
Accounts receivable		150,137
Prepaid expenses and other current assets	(237,475)	20,932
Decrease in deposits and other noncurrent assets		110,485
Inventory		83,750
Accounts payable	(248,115)	739,415
Accrued expenses	166,828	697,429
Accrued interest	549,703	464,279
Indebtedness to related parties	(501,599)	738,435
Net cash used in operating activities of continuing operations	(2,066,576)	(2,264,279)
Net cash used in operating activities of discontinued operations	(118,644)	(2,215,434)
Net cash used in operating activities	(2,185,220)	(4,479,713)
INVESTING ACTIVITIES:
Proceeds of note receivable	5,051,923
Acquisition of intangible assets	(292,675)	(91,862)
Net cash provided by/(used in) investing activities of continuing operations	4,759,248	(91,862)
Net cash used in investing activities of discontinued operations	(103,729)	(446,922)
Net cash provided by/(used in) investing activities	4,655,519	(538,784)
FINANCING ACTIVITIES:
Proceeds from issuance of common stock		790,225
Proceeds from warrant exercises	1,075,396	1,274,790
Proceeds from convertible notes payable	725,000	2,630,000
Proceeds from line of credit	375,000
Principal payment on notes payable and operating lease obligation	(3,156,014)	(84,869)
Principal payment on related party note	(151,923)
Brokerage fees from warrant exercises and stock issuances	(107,373)	(188,593)
Fees for issuance of convertible notes	(74,750)	(175,000)
Net cash provided by/(used in) financing activities of continuing operations	(1,314,664)	4,246,553
Net cash provided by/(used in) financing activities of discontinued operations	(161,768)	741,655
Net cash provided by/(used in) financing activities	(1,476,432)	4,988,208
NET CHANGE IN CASH AND CASH EQUIVALENTS	993,867	(30,289)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	151,766	182,055
CASH AND CASH EQUIVALENTS AT END OF YEAR	1,145,633	151,766
Less: cash and cash equivalents classified as discontinued operations	(352,593)	(149,360)
CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS	793,040	2,406
Cash paid for interest	241,014	451,040
Cash paid for income tax
Noncash investing and financing transactions:
Accrued liabilities forgiven in connection with Wellcana Note settlement	172,500
Depreciation capitalized in inventory (discontinued operations)	532,785	811,508
Accrued interest capitalized in convertible note principal	223,094
Property capitalized under operating leases		182,624
Patent acquisition costs capitalized in intangible assets	319,939	247,646
Stock options issued for preparing patent applications	168,000
Stock issued upon conversion of notes payable	160,000	525,000
Inducement dividend from warrant exercises	2,774,000	262,240
Cumulative effect of the new lease standard		7,550
Convertible Notes Payable [Member]
Noncash investing and financing transactions:
Beneficial conversion feature on notes payable	$ 543,886	$ 829,737

Note 1 - Background and Nature

Note 1 - Background and Nature of Operations	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company whose goal is to create patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. Through its wholly owned Canadian subsidiary, GBS Global Biopharma, Inc. (“GBSGB”), the Company is engaged in the research and development of plant-based medicines, primarily cannabinoid medicines, with virtual operations in North America and Europe. GBSGB's assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB's intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson's disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB's intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, 250,000,000 400,000,000. August 15, 2019, 400,000,000 600,000,000. Recent Developments Sale of Membership Interest in GB Sciences Louisiana, LLC On November 15, 2019, 50.01% $4,900,000 December 16, 2020, $4,900,000 (Note 13 Convertible Note Payable to Iliad Research and Trading, L.P. On April 23, 2019, 8% $2,765,000 April 22, 2020, July 14, 2020, $3,264,594 On November 20, 2020, $3,006,015 December 8, 2020, $3,006,015 $4,150,000 $3,006,015 (Note 6 Intellectual Property Portfolio On October 14th, 2020, In Silico in silico On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Planned Divestiture of Nevada Cannabis Operations On November 15, 2019, March 24, 2020, 100% $4,000,000 $4,000,000 8% (Note 14 On November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017, (Note 14 The sales of the Teco and Nopah Subsidiaries are expected to close upon the successful transfer of the Nevada cannabis cultivation and production licenses held by those subsidiaries. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19

Note 2 - Going Concern

Note 2 - Going Concern	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company's consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $103,886,232 March 31, 2021 $5,054,593 $439,979 March 31, 2021 $3,884,877 $243,787 March 31, 2020 $2,185,220 $118,644 year ended March 31, 2021 $4,479,713 $2,215,434 year ended March 31, 2020 Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no Furthermore, Management believes the COVID- 19 may not 19 In view of these conditions, the Company's ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no Discontinued Operations See Note 4 Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2021 2020 Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, 100% not $449,801 March 31, 2020, $1,021,067 $571,264. Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%. $4.0 $4.0M Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020 $352,274 $1,543,397, Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 158,404,020 March 31, 2021 2020 not Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operation

Note 4 - Discontinued Operations	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Louisiana, LLC, GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Louisiana cultivation and extraction facility (Note 13 (Note 14 There were no March 31, 2021 2020 March 31, 2021 2020 March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) The components of revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2021 2020 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 ) Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. During the year ended March 31, 2021 $24,768 $94,912 $70,144 March 31, 2021 2020 Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress includes live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. Inventory is included in current assets from discontinued operations in the Company's consolidated balance sheets at March 31, 2021 2020 March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839 Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $ 82,904 91,504 March 31, 2021 2020 March 31, 2021 2020 Leases In February 2016, 2016 02, 842 Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the standard. Lease payments do not April 1, 2019. not The Company adopted the New Lease Standard using the modified retrospective transition approach as of the effective date as permitted by the amendments in ASU 2018 11, 842 not April 1, 2019. The Company determines if an arrangement is a lease at inception and has had lease agreements for warehouses, office facilities, and equipment. As a result of the adoption of ASC 842 April 1, 2019, $182,624, $190,173 All of the Company's lease commitments previously recorded as operating leases have terminated as of March 31, 2021 March 31, 2021 March 31, 2021 2020 December 31, 2025 December 31, 2030. Operating leases are included in discontinued operations as operating lease right-of-use assets, operating lease obligations, current, and operating lease obligations, long term on the Company's balance sheets. Finance leases are included in property and equipment, finance lease obligations, current, and finance lease obligations, long term, on the Company's balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. The rates used to discount finance leases previously recorded as capital leases range from 10.2% 11.5%. 17.0%. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The lease costs recorded in the Company's financial statements for the years ended March 31, 2021 2020 March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653 The future minimum lease payments of lease liabilities, including the costs of the lease extension, classified as discontinued operations at March 31, 2021 Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 0% October 23, 2017 On October 23, 2017, 100% 100% one $500,000 0% $700,000 three January 1, 2018. $521,067 20.3% $178,933 To date, the Company has made principal payments totaling $330,555 $369,445 March 31, 2021 March 31, 2021 $13,929 March 31, 2021 $0. On August 10, 2020, (Note 14 $190,272. July 31, 2021, no no 15% 8% November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 (Note 14 $470,000 not March 31, 2021 $485,000 $15,000. $38,767 March 31, 2021 $485,000 March 31, 2021 8% May 7, 2020 On May 7, 2020, $135,000 $15,000 $150,000 8.0% first $8,000,000 8,002,500 $0.04. $272,085 $49,525 $222,560. $150,000. March 31, 2021 $154,964 $4,964 $150,000 $154,964 October 5, 2020, 8% July 24, 2020 On July 24, 2020, 8% "July 24 $500,000 may 8% February 28, 2019. July 24 $4,000,000 3 July 24 may (Note 14 On December 29, 2020, $975,000 three $325,000 July 24 $3,025,000. July 24 $325,000 one $4,000,000 not July 24 $650,000 two $325,000 $325,000 July 24 $50,000 $325,000 $1,025,000 March 31, 2021 $12,510 March 31, 2021 Summary of Notes Payable As of March 31, 2021 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 6 - Convertible Notes

Note 6 - Convertible Notes	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 March 2017 July 2017 In March 2017, third $1,000 6% 4,000 $0.25 4,000 $0.60 three March 2017 May 2017, $2,000,000. three 8,000,000 8,000,000 one $0.60 three $1,933,693, $904,690 $1,029,003 In July 2017, third $1,000 6% 4,000 $0.25 4,000 $0.65 three July 2017 December 2017, $7,201,000. three 28,804,000 28,804,000 one $0.60 three $7,092,796, $3,142,605 $3,950,191 All notes from the March July 2017 March 31, 2021 $197,000 $1,257,000 $197,000 $0.10 788,000 three $0.10 September 30, 2023. $13,396 $33,490. 10% $46,886 $28,306 March 31, 2021 $22,412 $197,000 $44,332 March 31, 2021 $38,438 Three convertible notes totaling $1,060,000 not March 31, 2021 $208,779, $139,253 $1,060,000 $228,373 March 31, 2021 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, $1,500,000 8% August 28, 2020, 8,823,529 $0.17 100% $176,471 On May 28, 2019, $170,000 8% February 28, 2019. 1,000,000 $0.17 $17,225 $152,775. $1,330,000. On July 12, 2019, 8% $100,000 $100,000 July 12, 2019, $41,863 $0.11 The Company evaluated the modification under the guidance in ASC 470 50 10% $1,338,057, $133,806, $124,158. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On October 23, 2019, October 23, 2019 $0.08 We evaluated the modification under the guidance in ASC 470 50 10% 2nd $1,269,067, $92,796, $92,796 March 31, 2020. On November 27, 2019, 8% “2nd 2nd $0.04 $30,000 We evaluated the modification under the guidance in ASC 470 50 2nd 10% 2nd no 2nd $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 On December 29, 2020, (Note 14 November 30, 2020. During the quarter ended March 31, 2021, $160,000 $0.04 4,000,000 $1,111,863 March 31, 2021 During the year ended March 31, 2021 $477,500 $68,019 $409,481 $1,256,857 $4,000,000 no 8% April 23, 2019 On April 23, 2019, 8% $2,765,000. $265,000 $0.17 April 22, 2020. $440,000 $265,000 $175,000 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 On April 22, 2020, 10%. $9,559 10% $276,500 10% On May 20, 2020, July 14, 2020, $3,264,594 15% On November 20, 2020, $3,006,015 (Note 14 December 8, 2020. December 8, 2020, December 9, 2020, $25,000 $25,000 $3,006,015 not December 16, 2020, $3,006,015 December 18, 2020, no During the year ended March 31, 2021 $379,956, $29,831 $140,833 $209,292 $25,000 $3,264,594 $209,292 $3,473,886, $467,872. December 2020 $575,000 6% On December 18, 2020, 6.0% 19 $0.05 March 31, 2021 $575,000 three $325,000 December 2021, $250,000 December 2023. $500,250, 74,750. $425,000 $347,000 At March 31, 2021 $28,496 $296,504. $135,971 $114,029. $16,354 March 31, 2021 $11,217

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $34,555 $541,462 year ended March 31, 2021 2020 $532,785 $811,508. $21,855 $424,501 March 31, 2021 2020 March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269 During the year ended March 31, 2020 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%.

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company's effective tax rate was - 3.6% 0.0% March 31, 2021 2020 Income tax expense was $168,527 March 31, 2021 $48,076 $486,145 March 31, 2018 March 31, 2021 $761,509 $486,145 March 31, 2018 $154,914. $86,837 March 31, 2020 March 31, 2018 $592,982 March 31, 2020 March 31, 2021 2020 Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2021 2020 51,776,062 50,596,940 34,481,122 2025 2039. 17,294,940 March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837 The tax effects of the primary temporary differences giving rise to the Company's deferred tax assets and liabilities are as follows for the year ended March 31, 2021 and 2020 2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2021 not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2018

Note 9 - Capital Transactions

Note 9 - Capital Transactions	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 9 Year Ended March 31, 2021 On April 1, 2020, $0.03 $.05 35,798,809 March 31, 2021 968,023 ( 107,373 $1,591,080 During the year ended March 31, 2021 3,500,000 one $0.05 ten $168,000 During the year ended March 31, 2021 788,000 three $0.10 three $197,000 (Note 6 $13,396. On November 16, 2020, 450,000 $0.03. November 16, 2025, June 1, 2023. $4,950 $11,250 $6,300. On December 7, 2020, 3,500,000 $0.04 ten $133,000 $133,000 On December 15, 2020, 3,250,000 $0.05 ten one third one third one one third two $156,000 $62,000 March 31, 2021 $78,000 March 31, 2021 On December 15, 2020, 6,050,000 $0.05, $199,600 $250,650 $51,050. On January 2, 2021, 9,424,613 $0.01, January 2, 2024. December 11, 2020 October 1, 2023, $0.25 $1.00. $367,196 $135,861, $231,335. During the quarter ended March 31, 2021, $160,000 $0.04 4,000,000 (Note 6 On February 8, 2021, 42,705,809 December 2019 three $0.10 $1,182,920 At March 31, 2021 85,843,036 $0.01 $0.90 17,733,334 $0.11 5,883,000 $0.14 Year Ended March 31, 2020 Stock Issued for Debt Conversions During the year ended March 31, 2020, 7,583,333 On May 28, 2019, $170,000 8% February 28, 2019 ( 6 1,000,000 $0.17 $17,225 $152,775. On August 1, 2019, $110,000 $0.11 1,000,000 $9,579 $100,421. $1,361,863. On December 16, 2019, $120,000 $0.04 3,000,000 $57,551 $62,449. $1,271,863 $687,021, $584,842 During the year ended March 31, 2020, $125,000 October 30, 2019, $75,000 $0.06 1,250,000 $64,706, November 18, 2019, $50,000 $0.0375 1,333,333 $62,353, $127,059 two March 31, 2020. Exercise of Warrants for Stock During the year ended March 31, 2020, 17,563,000 In order to encourage the exercise of approximately 70.5 $0.65 $0.30, $0.10 July 11, 2019. July 12, 2019, August 30, 2019, July 31, 2019, December 31, 2019. 9,449,750 $850,478, $94,498. $230,025. In order to encourage the further exercise of the warrants, the Company effected a temporary decrease in the exercise price of the warrants to $0.03 $.05 December 2019. 8,113,250 $307,249, $22,566. $32,215. Issuance of Stock for Services During the year ended March 31, 2020, 2,100,000 $214,000 Warrants Outstanding Presented below is a summary of the Company's warrant activity, exclusive of warrants held by employees (see Note 10 March 31, 2021 2020 Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.030 0.035 Warrants expired/cancelled (6,390,125) 0.60 0.90 Outstanding at March 31, 2021 85,843,036

Note 10 - Employee Benefit Plan

Note 10 - Employee Benefit Plan	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 10 Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 4,500,000 may 2014 June 30, 2015, 8 8,500,000 April 6, 2018, 2014 2018 October 25, 2018, 8 10,000,000 2018 2,022,443 March 31, 2021 Compensation Expense For the years ended March 31, 2021 2020 436,349 287,260 $211,000 $103,472, no $78,000 March 31, 2021 Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2021 2020 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 The table below sets forth nonemployee option activity for the years ended March 31, 2021 2020 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14 Restricted stock awards No March 31, 2021 2020

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 On September 18, 2017, five two five $500,000 50% $250,000 $500,000 three $750,000. August 4, 2020, first $250,000 twelve September 30, 2020, twelve August 24, 2020, $250,000 no (Note 14 An individual filed a Charge of Discrimination with the Nevada Equal Rights Commission ("NERC") against the Company on April 2, 2019, May 11, 2021. On April 22, 2020, May 20, 2020, July 14, 2020, $3,264,594. December 16, 2020, $3,006,014 (Note 6 On April 22, 2020, $73,050 September 17, 2020, $25,000 $48,050. From time to time, the Company may not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 12 As of March 31, 2021 84,913 On September 1, 2019, $20,000 9 January 2, 2021, $57,000 $114,159 $57,159, On November 16, 2020, $84,745 $78,245 $6,500 $44,192 March 31, 2021 March 31, 2020 $40,192 In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 first August 4, 2020, first (Note 14

Note 13 - Sale of 50% Membershi

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC	12 Months Ended
	Mar. 31, 2021
GB Sciences Louisiana, LLC, Sale of Equity [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 13 50% On November 15, 2019, 50.01% $8,000,000 $8,000,000 The Wellcana note bore interest at a rate of 5% June 1, 2020 December 1, 2021. $1,389,408 17.0%, $6,610,592 November 15, 2019: November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592 Upon close of the sale on November 15, 2019, 4,393,242 As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242 On August 24, 2020, $5,224,423, $151,923, $172,500 $4,900,000 October 15, 2020, $8,000,000 $250,000 (Note 11 no $750,000 September 1, 2020, $500,000. As a result of the August 24, 2020 March 31, 2020 $5,224,423 August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 ) The Company received payments from Wellcana totaling $550,000 August September 2020, $151,923 $172,500 $4,350,000. On October 15, 2020, $4,350,000 October 15, 2020, $4,350,000 December 8, 2020. $4,350,000 $250,000, $4,350,000 December 8, 2020. October 24, 2020, $250,000 October 29, 2020. On December 8, 2020, $250,000 $50,000 December 8, 2020, not $4,350,000 December 16, 2020, $4,150,000, The Company's statements of operations and cash flows for the year ended March 31, 2020 November 15, 2019,

Note 14 - Sale of 100% Membersh

Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries	12 Months Ended
	Mar. 31, 2021
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 14 100% On November 15, 2019, 75% $3,000,000 $3,000,000 $470,000 (Note 5 On March 24, 2020, 100% $4,000,000 $4,000,000 8% 36 30 On July 24, 2020, 8% "July 24 July 24 $4,000,000 3 July 24 March 31, 2021 $375,000 July 24 (Note 5 On December 29, 2020, $975,000 $3,025,000, $325,000 one three not July 24 $650,000 July 24 three $325,000, $1,025,000, $4,000,000 The Omnibus Amendment also amends the Management Services Agreement to provide that no November 30, 2020. March 31, 2021 $850,000 $4,000,000 three 36 30 The sale is expected to close upon the successful transfer of the Nevada cultivation and production licenses. The transfer of cannabis licenses in the State of Nevada was subject to an indefinite moratorium beginning in October 2019. July 21, 2020, 90 19 The Company also holds a Nevada license for cultivation of medical marijuana located in Sandy Valley, Nevada (the “Nopah License”). The license is owned by the Company's wholly owned subsidiary, GB Sciences Nopah, LLC ("Nopah"). Operations have not November 27, 2019, 100% August 10, 2020, $300,000 $300,000 0% October 23, 2017 (Note 5 Because the moratorium on license transfers has been lifted, the Company determined that the Teco Facility and Nopah Facility qualify for presentation as discontinued operations, and the income, assets, and cash flows of the Teco Subsidiaries and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements.

Note 15 - Concentrations

Note 15 - Concentrations	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 15 For the year ended March 31, 2021 three 18.4%, 16.7%, 13.3% March 31, 2021 two 26% 13% $513,901 March 31, 2021 March 31, 2021 $3,120,620 March 31, 2020 $3,120,620, 85%, $569,077, 15%,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	Note 16 On May 11, 2021, $200,000 December 31, 2021. On June 14, 2021, 1,672,000 $0.03 $50,160

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, the assets, liabilities, income, and cash flows of GB Sciences Nevada LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC, have been separated from the comparative period amounts to conform to the current period presentation as discontinued operations as the result of the pending sale of the Company's Nevada operations. The reclassifications had no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations See Note 4
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three no March 31, 2021 2020
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections.
Inventory, Policy [Policy Text Block]	Inventory We value our inventory at the lower of the actual cost of our inventory, as determined using the first first
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Indefinite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also include the acquisition cost of a cannabis production license with an indefinite life. We amortize our finite-lived intangible assets over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. During the year ended March 31, 2020, 100% not $449,801 March 31, 2020, $1,021,067 $571,264.
Lessee, Leases [Policy Text Block]	Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and has lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprise a significant portion of our total assets from discontinued operations. We evaluate the carrying value of property and equipment if impairment indicators are present or if other circumstances indicate that impairment may March 31. may not During the year ended March 31, 2020, 100% (Note 14 not $8.0 $11.9 $7.3 $4,645,054 3 820. 17%. $4.0 $4.0M
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board's (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company's only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2021 2020 $352,274 $1,543,397,
Share-based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company's basic loss per share has been calculated using the weighted average number of common shares outstanding during the period. The Company had 164,049,941 158,404,020 March 31, 2021 2020 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Recently Adopted Standards In August 2018, No. 2018 13, December 15, 2019, April 1, 2020, not Standards Not In May 2021, No. 2021 04, 2021 04 April 1, 2022. 2021 04 On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operati_2

Note 4 - Discontinued Operations (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	March 31, 2021 March 31, 2020 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 793,040 $ 352,593 $ 1,145,633 $ 2,406 $ 149,360 $ 151,766 Accounts receivable, net - 400,175 400,175 - 117,967 117,967 Inventory, net - 1,689,304 1,689,304 - 1,445,839 1,445,839 Prepaid and other current assets 256,251 52,492 308,743 18,776 42,109 60,885 Note receivable - - - 5,224,423 - 5,224,423 TOTAL CURRENT ASSETS 1,049,291 2,494,564 3,543,855 5,245,605 1,755,275 7,000,880 Property and equipment, net 25,022 4,876,247 4,901,269 37,821 5,496,012 5,533,833 Intangible assets, net 1,706,762 571,264 2,278,026 1,128,702 571,264 1,699,966 Deposits and other noncurrent assets - 82,904 82,904 - 91,504 91,504 Operating lease right-of-use assets, net - - - - 26,685 26,685 TOTAL ASSETS $ 2,781,075 $ 8,024,979 $ 10,806,054 $ 6,412,128 $ 7,940,740 $ 14,352,868 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,412,459 $ 509,477 $ 1,921,936 $ 1,913,049 $ 646,865 $ 2,559,914 Accrued interest 493,741 49,211 542,952 366,865 30,787 397,652 Accrued expenses 957,946 105,421 1,063,367 813,618 74,394 888,012 Notes and convertible notes payable, net 3,594,804 485,000 4,079,804 5,054,728 480,000 5,534,728 Indebtedness to related parties 84,913 - 84,913 586,512 - 586,512 Note payable to related party - - - 151,923 - 151,923 Income tax payable - 761,509 761,509 - 592,982 592,982 Finance lease obligations, current - 143,967 143,967 - 166,769 166,769 Operating lease obligations, current - - - - 7,265 7,265 TOTAL CURRENT LIABILITIES 6,543,863 2,054,585 8,598,448 8,886,695 1,999,062 10,885,757 Convertible notes payable, net 292,410 - 292,410 - - - Operating lease obligations, long term - - - - 22,515 22,515 Finance lease obligations, long term - 3,389,124 3,389,124 - 3,533,090 3,533,090 TOTAL LIABILITIES $ 6,836,273 $ 5,443,709 $ 12,279,982 $ 8,886,695 $ 5,554,667 $ 14,441,362 For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Continuing Discontinued Total Continuing Discontinued Total Sales revenue $ - $ 4,110,456 $ 4,110,456 $ - $ 3,689,697 $ 3,689,697 Cost of goods sold - (3,506,722 ) (3,506,722 ) - (4,576,627 ) (4,576,627 ) Gross profit (loss) - 603,734 603,734 - (886,930 ) (886,930 ) General and administrative expenses 2,001,617 276,986 2,278,603 5,741,514 2,034,612 7,776,126 Loss on impairment of long-lived assets - - - - 4,645,054 4,645,054 LOSS FROM OPERATIONS (2,001,617 ) 326,748 (1,674,869 ) (5,741,514 ) (7,566,596 ) (13,308,110 ) OTHER INCOME/(EXPENSE) Gain/(loss) on extinguishment 467,872 - 467,872 (216,954 ) - (216,954 ) Gain on settlement of accounts payable 422,414 54,958 477,372 - - - Gain on deconsolidation - - - 4,393,242 - 4,393,242 Interest expense (1,285,460 ) (486,481 ) (1,771,941 ) (1,109,031 ) (694,313 ) (1,803,344 ) Loss on modification of line of credit (650,000 ) - (650,000 ) - - - Loss on modification of note receivable - - - (1,895,434 ) - (1,895,434 ) Debt default penalty (286,059 ) - (286,059 ) - - - Other expense - (118,875 ) (118,875 ) (179,368 ) (14,880 ) (194,248 ) TOTAL OTHER INCOME/(EXPENSE) (1,331,233 ) (550,398 ) (1,881,631 ) 992,455 (709,193 ) 283,262 NET LOSS BEFORE INCOME TAXES (3,332,850 ) (223,650 ) (3,556,500 ) (4,749,059 ) (8,275,789 ) (13,024,848 ) Income tax expense - (168,527 ) (168,527 ) - (86,837 ) (86,837 ) NET LOSS $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) $ (4,749,059 ) $ (8,362,626 ) $ (13,111,685 ) For the Year Ended March 31, For the Year Ended March 31, 2021 2020 Nevada Louisiana Total Nevada Louisiana Total Sales revenue $ 4,110,456 $ - $ 4,110,456 $ 3,120,620 $ 569,077 $ 3,689,697 Cost of goods sold (3,506,722 ) - (3,506,722 ) (4,002,083 ) (574,544 ) (4,576,627 ) Gross profit (loss) 603,734 - 603,734 (881,463 ) (5,467 ) (886,930 ) General and administrative expenses 276,986 - 276,986 741,999 1,292,613 2,034,612 Loss on impairment of long-lived assets - - - 4,645,054 - 4,645,054 LOSS FROM OPERATIONS 326,748 - 326,748 (6,268,516 ) (1,298,080 ) (7,566,596 ) OTHER INCOME/(EXPENSE) Gain on settlement of accounts payable 54,958 - 54,958 - - - Interest expense (486,481 ) - (486,481 ) (516,173 ) (178,140 ) (694,313 ) Other expense (118,875 ) - (118,875 ) (14,880 ) - (14,880 ) TOTAL OTHER INCOME/(EXPENSE) (550,398 ) - (550,398 ) (531,053 ) (178,140 ) (709,193 ) NET LOSS BEFORE INCOME TAXES (223,650 ) - (223,650 ) (6,799,569 ) (1,476,220 ) (8,275,789 ) Income tax expense (168,527 ) - (168,527 ) (86,837 ) - (86,837 ) NET LOSS $ (392,177 ) $ - $ (392,177 ) $ (6,886,406 ) $ (1,476,220 ) $ (8,362,626 )
Lease, Cost [Table Text Block]	March 31, Classification on the Statements of Operations 2021 2020 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 154,699 $ 252,973 Finance leases - interest on lease liabilities Loss from discontinued operations 414,993 426,374 Operating leases Loss from discontinued operations 3,243 13,648 Total lease cost, discontinued operations 572,935 692,995 Operating leases, continuing operations General and administrative expense - 61,658 Total lease cost $ 572,935 $ 754,653
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2021 March 31, 2020 Raw materials $ 86,076 $ 91,465 Work in progress 743,844 1,166,511 Finished goods 866,195 466,319 Subtotal 1,696,115 1,724,295 Allowance to reduce inventory to NRV (6,811 ) (278,456 ) Total inventory, net $ 1,689,304 $ 1,445,839
Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]	Year Ending March 31, Finance Leases 2022 $ 544,296 2023 560,625 2024 577,444 2025 594,767 2026 612,610 Thereafter 3,168,492 Total minimum lease payments 6,058,234 Less: Amount representing interest (2,525,143 ) Present value of minimum lease payments 3,533,091 Less: Current maturities of capital lease obligations (143,967 ) Long-term capital lease obligations $ 3,389,124

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Debt [Table Text Block]	As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410 As of March 31, 2020 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ (13,929 ) $ 355,516 8% Line of Credit dated November 27, 2019 (Note 5) 480,000 - 480,000 6% Convertible promissory notes payable (Note 6) 1,257,000 (155,340 ) 1,101,660 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,271,863 (409,481 ) 862,382 8% Convertible Promissory Note dated April 23, 2019 (Note 6) 2,765,000 (29,830 ) 2,735,170 Total short term notes and convertible notes payable 6,143,308 (608,580 ) 5,534,728 Less: Notes payable classified as discontinued operations (480,000 ) - (480,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 5,663,308 $ (608,580 ) $ 5,054,728

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2021 Continuing Operations Discontinued Operations Total Furniture and fixtures $ - $ - $ - Computer and software 151,748 - 151,748 Machinery and equipment 619,631 289,035 908,666 Leaseholds - 3,455,600 3,455,600 Construction in progress - 21,069 21,069 Finance lease right-of-use asset - 1,663,013 1,663,013 771,379 5,428,717 6,200,097 Less accumulated depreciation and amortization (746,357 ) (552,471 ) (1,298,828 ) Property and Equipment, Net $ 25,022 $ 4,876,247 $ 4,901,269

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2021 2020 Tax benefit computed at U.S. statutory rates $ (697,040 ) $ (2,178,478 ) Increases (decreases) in taxes resulting from: IRC Section 280E 173,045 202,877 Other permanent items 14,407 22,948 Change in valuation allowance 26,720 1,952,653 Adjustments to valuation of deferred tax assets 603,319 - Total provision for income taxes 120,451 - Penalties and interest on prior year tax liabilities 48,076 86,837 Total income tax expense $ 168,527 $ 86,837 The tax effects of the primary temporary differences giving rise to the Company's deferred tax assets and liabilities are as follows for the year ended March 31, 2021 and 2020
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2021 2020 Deferred tax assets: Stock based compensation $ 3,131,344 $ 2,943,816 Net operating loss carryforward 10,460,788 10,625,357 Impairment of long-lived assets 975,461 975,461 Depreciation and Amortization expense (458,938 ) (324,707 ) Other temporary items 220,795 136,243 Total deferred tax assets 14,329,450 14,356,170 Less valuation allowance (14,329,450 ) (14,356,170 ) Net deferred tax asset $ - $ -

Note 9 - Capital Transactions (

Note 9 - Capital Transactions (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2019 99,790,989 Warrants issued 7,622,780 $0.30 Warrants exercised (17,563,000) 0.035 0.10 Warrants expired/cancelled (5,312,608) 0.50 2.00 Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.030 0.035 Warrants expired/cancelled (6,390,125) 0.60 0.90 Outstanding at March 31, 2021 85,843,036

Note 10 - Employee Benefit Pl_2

Note 10 - Employee Benefit Plan (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended March 31, 2021 March 31, 2020 Weighted-average volatility 127 % N/A Expected term (in years) 10 N/A Risk-free interest rate 0.93 % N/A
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 12,583,334 $ 0.28 7.18 $ 43,000 Granted - Exercised - Forfeited (1,600,000 ) $ 0.27 Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.045 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Fully vested and expected to vest at March 31, 2021 17,733,334 $ 0.11 Exercisable at March 31, 2021 15,566,668 $ 0.12 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2019 2,383,000 $ 0.27 7.76 $ 492,250 Granted - Exercised - Forfeited - Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ 35,000 Fully vested and expected to vest at March 31, 2021 5,883,000 $ 0.14 Exercisable at March 31, 2021 5,883,000 $ 0.14

Note 13 - Sale of 50% Members_2

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Tables)	12 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Note Receivable with Imputed Interest [Table Text Block]	November 15, 2019 Note Receivable Note Payments June 1, 2020 $ 500,000 September 1, 2020 750,000 December 1, 2020 1,000,000 March 1, 2020 1,250,000 June 1, 2021 1,500,000 September 1, 2021 1,500,000 December 1, 2021 1,500,000 Total proceeds 8,000,000 Discount on note receivable (1,389,408 ) Net present value $ 6,610,592
Schedule of Deconsolidation [Table Text Block]	As of Gain on Deconsolidation November 15, 2019 Present value of promissory note $ 6,610,592 Carrying amount of non-controlling interest 8,707,651 Total 15,318,243 Carrying amount of assets 14,715,798 Carrying amount of liabilities (3,790,797 ) Net assets deconsolidated 10,925,001 Gain on deconsolidation $ 4,393,242
Schedule of Gain (Loss) on Notes Receivable Modification [Table Text Block]	August 24, 2020 Modification March 31, 2020 Total cash payments to be made by October 15, 2020 $ 4,900,000 Liabilities to be forgiven upon receipt of October 15, 2020 payment 324,423 Total receivable (as modified) 5,224,423 Carrying value of note receivable as of March 31, 2020 6,969,720 Accrued interest as of March 31, 2020 150,137 Total amount receivable (prior to modification) 7,119,857 Loss on modification of note receivable $ (1,895,434 )

Note 1 - Background and Natur_2

Note 1 - Background and Nature of Operations (Details Textual) - USD ($)	Dec. 16, 2020	Jul. 14, 2020	Mar. 24, 2020	Nov. 27, 2019	Nov. 15, 2019	Dec. 08, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Nov. 20, 2020	Aug. 10, 2020	Aug. 15, 2019	Apr. 23, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)								600,000,000	600,000,000			600,000,000		400,000,000	250,000,000
Teco [Member]
Sale of Stock, Percentage of Ownership			100.00%		100.00%				100.00%
Proceeds from Collection of Notes Receivable									$ 4,000,000
Proceeds from Divestiture of Businesses			$ 4,000,000		$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total			$ 4,000,000		$ 4,000,000
Notes Receivable, Interest Rate			8.00%		8.00%
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage													8.00%
Debt Instrument, Face Amount									2,765,000				$ 2,765,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member]
Litigation Settlement, Amount Agreed to Be Paid to Offended Party										$ 3,006,015
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member] | Wellcana Plus LLC [Member]
Payments Received Under Modified Note Receivable						$ 4,150,000
Payments for Legal Settlements, Amount Paid Directly to Offended Party						$ 3,006,015
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594						$ 3,264,594
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Face Amount								$ 369,445	369,445
Wellcana Note [Member]
Proceeds from Collection of Notes Receivable	$ 4,900,000						$ 4,900,000
Financing Receivable, after Allowance for Credit Loss, Total									$ 7,119,857
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership					50.01%
Wellcana Plus LLC [Member] | Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judgment Settlement Agreement [Member]
Litigation Settlement, Amount Agreed to Be Paid to Offended Party, Amount Agreed By Other Counterparty to Be Paid Directly to Offended Party										$ 3,006,015
GB Sciences Nopah, LLC [Member]
Sale of Interest, Percentage of Ownership				100.00%
Sale of Interest, Consideration to Be Received on Transaction											$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage											0.00%
Sale of Interest, Consideration to Be Received on Transaction, Reduction to Balance of Debt Instrument											$ 300,000

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance	$ (103,886,232)	$ (97,387,205)
Working Capital (Deficit)	(5,054,593)	(3,884,877)
Net Cash Provided by (Used in) Operating Activities, Total	(2,185,220)	(4,479,713)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	(118,644)	(2,215,434)
Discontinued Operations [Member]
Working Capital (Deficit)	$ 439,979	$ 243,787

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Short-term Investments, Total			$ 0	$ 0
Research and Development Expense, Total			$ 352,274	$ 1,543,397
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)			164,049,941	158,404,020
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)			3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)			8 years
Production License [Member]
Asset Impairment Charges, Total				$ 449,801
Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance				$ 571,264	$ 1,021,067
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%		100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Proceeds from Collection of Notes Receivable				$ 4,000,000

Note 4 - Discontinued Operati_3

Note 4 - Discontinued Operations (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Apr. 01, 2019
Lessee, Operating Lease, Discount Rate	17.00%
Minimum [Member]
Lessee, Finance Lease, Discount Rate	10.20%
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset			$ 182,624
Operating Lease, Liability, Total			$ 190,173
Discontinued Operations [Member]
Accounts Receivable, Allowance for Credit Loss, Recovery	$ 24,768
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease), Total	(94,912)
Accounts Receivable, Allowance for Credit Loss, Writeoff	70,144
Deposits Assets, Noncurrent	82,904	$ 91,504
Operating Lease, Right-of-Use Asset		26,685
GB Sciences Louisiana, LLC [Member]
Disposal Group, Including Discontinued Operation, Assets, Total	0	0
Disposal Group, Including Discontinued Operation, Liabilities, Total	$ 0	$ 0

Note 4 - Discontinued Operati_4

Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Cash		$ 793,040	$ 2,406
Prepaid and other current assets		256,251	18,776
Note receivable			5,224,423
TOTAL CURRENT ASSETS		3,543,855	7,000,880
Property and equipment, net		25,022	37,821
Intangible assets, net		1,706,762	1,128,702
TOTAL ASSETS		10,806,054	14,352,868
Accounts payable		1,412,459	1,913,049
Accrued interest		493,741	366,865
Accrued expenses		957,946	813,618
Notes and convertible notes payable, net		3,594,804	5,054,728
Indebtedness to related parties		84,913	586,512
Note payable to related party			151,923
Income tax payable		761,509	592,982
TOTAL CURRENT LIABILITIES		8,598,448	10,885,757
Convertible notes payable, net		292,410
TOTAL LIABILITIES		12,279,982	14,441,362
Sales revenue
Cost of goods sold
Gross profit (loss)
General and administrative expenses		2,001,617	5,741,514
Gain/(loss) on extinguishment		467,872	(216,954)
Gain on settlement of accounts payable		422,414
Gain on deconsolidation	$ 4,393,242		4,393,242
Interest expense		(1,285,460)	(1,109,031)
Loss on modification of line of credit		(650,000)
Loss on modification of note receivable			(1,895,434)
Debt default penalty		(286,059)
Total other income/(expense)		(1,331,233)	992,455
Income tax expense (Note 8)
NET LOSS		(392,177)	(8,362,626)
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Inventory, net		1,689,304	1,445,839
Finance lease obligations, current		143,967
Finance lease obligations, long term		3,389,124
Sales revenue		4,110,456	3,689,697
Cost of goods sold		(3,506,722)	(4,576,627)
Gross profit (loss)		603,734	(886,930)
General and administrative expenses		276,986	2,034,612
Loss on impairment of long-lived assets			4,645,054
LOSS FROM OPERATIONS		326,748	(7,566,596)
Gain on settlement of accounts payable		54,958
Interest expense		(486,481)	(694,313)
Other expense		(118,875)	(14,880)
Total other income/(expense)		(550,398)	(709,193)
NET LOSS BEFORE INCOME TAXES		(223,650)	(8,275,789)
Income tax expense (Note 8)		(168,527)	(86,837)
NET LOSS		(392,177)	(8,362,626)
Nevada Subsidiaries [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue		4,110,456	3,120,620
Cost of goods sold		(3,506,722)	(4,002,083)
Gross profit (loss)		603,734	(881,463)
General and administrative expenses		276,986	741,999
Loss on impairment of long-lived assets			4,645,054
LOSS FROM OPERATIONS		326,748	(6,268,516)
Gain on settlement of accounts payable		54,958
Interest expense		(486,481)	(516,173)
Other expense		(118,875)	(14,880)
Total other income/(expense)		(550,398)	(531,053)
NET LOSS BEFORE INCOME TAXES		(223,650)	(6,799,569)
Income tax expense (Note 8)		(168,527)	(86,837)
NET LOSS		(392,177)	(6,886,406)
GB Sciences Louisiana, LLC [Member]
Gain on deconsolidation	$ 4,393,242
GB Sciences Louisiana, LLC [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Sales revenue			569,077
Cost of goods sold			(574,544)
Gross profit (loss)			(5,467)
General and administrative expenses			1,292,613
Loss on impairment of long-lived assets
LOSS FROM OPERATIONS			(1,298,080)
Gain on settlement of accounts payable
Interest expense			(178,140)
Other expense
Total other income/(expense)			(178,140)
NET LOSS BEFORE INCOME TAXES			(1,476,220)
Income tax expense (Note 8)
NET LOSS			(1,476,220)
Continuing Operations [Member]
Cash		793,040	2,406
Accounts receivable, net
Inventory, net
Prepaid and other current assets		256,251	18,776
Note receivable			5,224,423
TOTAL CURRENT ASSETS		1,049,291	5,245,605
Property and equipment, net		25,022	37,821
Intangible assets, net		1,706,762	1,128,702
Deposits and other noncurrent assets
Operating lease right-of-use assets, net
TOTAL ASSETS		2,781,075	6,412,128
Accounts payable		1,412,459	1,913,049
Accrued interest		493,741	366,865
Accrued expenses		957,946	813,618
Notes and convertible notes payable, net		3,594,804	5,054,728
Indebtedness to related parties		84,913	586,512
Note payable to related party			151,923
Income tax payable
Finance lease obligations, current
Operating lease obligations, current
TOTAL CURRENT LIABILITIES		6,543,863	8,886,695
Convertible notes payable, net		292,410
Operating lease obligations, long term
Finance lease obligations, long term
TOTAL LIABILITIES		6,836,273	8,886,695
Sales revenue
Cost of goods sold
Gross profit (loss)
General and administrative expenses		2,001,617	5,741,514
Loss on impairment of long-lived assets
LOSS FROM OPERATIONS		(2,001,617)	(5,741,514)
Gain/(loss) on extinguishment		467,872	(216,954)
Gain on settlement of accounts payable		422,414
Gain on deconsolidation			4,393,242
Interest expense		(1,285,460)	(1,109,031)
Loss on modification of line of credit		(650,000)
Loss on modification of note receivable			(1,895,434)
Debt default penalty		(286,059)
Other expense			(179,368)
Total other income/(expense)		(1,331,233)	992,455
NET LOSS BEFORE INCOME TAXES		(3,332,850)	(4,749,059)
Income tax expense (Note 8)
NET LOSS		(3,332,850)	(4,749,059)
Discontinued Operations [Member]
Cash		352,593	149,360
Accounts receivable, net		400,175	117,967
Inventory, net		1,689,304	1,445,839
Prepaid and other current assets		52,492	42,109
Note receivable
TOTAL CURRENT ASSETS		2,494,564	1,755,275
Property and equipment, net		4,876,247	5,496,012
Intangible assets, net		571,264	571,264
Deposits and other noncurrent assets		82,904	91,504
Operating lease right-of-use assets, net			26,685
TOTAL ASSETS		8,024,979	7,940,740
Accounts payable		509,477	646,865
Accrued interest		49,211	30,787
Accrued expenses		105,421	74,394
Notes and convertible notes payable, net		485,000	480,000
Indebtedness to related parties
Note payable to related party
Income tax payable		761,509	592,982
Finance lease obligations, current		143,967	166,769
Operating lease obligations, current			7,265
TOTAL CURRENT LIABILITIES		2,054,585	1,999,062
Convertible notes payable, net
Operating lease obligations, long term			22,515
Finance lease obligations, long term		3,389,124	3,533,090
TOTAL LIABILITIES		5,443,709	5,554,667
Sales revenue		4,110,456	3,689,697
Cost of goods sold		(3,506,722)	(4,576,627)
Gross profit (loss)		603,734	(886,930)
General and administrative expenses		276,986	2,034,612
Loss on impairment of long-lived assets			4,645,054
LOSS FROM OPERATIONS		326,748	(7,566,596)
Gain/(loss) on extinguishment
Gain on settlement of accounts payable		54,958
Gain on deconsolidation
Interest expense		(486,481)	(694,313)
Loss on modification of line of credit
Loss on modification of note receivable
Debt default penalty
Other expense		(118,875)	(14,880)
Total other income/(expense)		(550,398)	(709,193)
NET LOSS BEFORE INCOME TAXES		(223,650)	(8,275,789)
Income tax expense (Note 8)		(168,527)	(86,837)
NET LOSS		(392,177)	(8,362,626)
Segment, Continuing and Discontinued Operations [Member]
Cash		1,145,633	151,766
Accounts receivable, net		400,175	117,967
Inventory, net		1,689,304	1,445,839
Prepaid and other current assets		308,743	60,885
Note receivable			5,224,423
TOTAL CURRENT ASSETS		3,543,855	7,000,880
Property and equipment, net		4,901,269	5,533,833
Intangible assets, net		2,278,026	1,699,966
Deposits and other noncurrent assets		82,904	91,504
Operating lease right-of-use assets, net			26,685
TOTAL ASSETS		10,806,054	14,352,868
Accounts payable		1,921,936	2,559,914
Accrued interest		542,952	397,652
Accrued expenses		1,063,367	888,012
Notes and convertible notes payable, net		4,079,804	5,534,728
Indebtedness to related parties		84,913	586,512
Note payable to related party			151,923
Income tax payable		761,509	592,982
Finance lease obligations, current		143,967	166,769
Operating lease obligations, current			7,265
TOTAL CURRENT LIABILITIES		8,598,448	10,885,757
Convertible notes payable, net		292,410
Operating lease obligations, long term			22,515
Finance lease obligations, long term		3,389,124	3,533,090
TOTAL LIABILITIES		12,279,982	14,441,362
Sales revenue		4,110,456	3,689,697
Cost of goods sold		(3,506,722)	(4,576,627)
Gross profit (loss)		603,734	(886,930)
General and administrative expenses		2,278,603	7,776,126
Loss on impairment of long-lived assets			4,645,054
LOSS FROM OPERATIONS		(1,674,869)	(13,308,110)
Gain/(loss) on extinguishment		467,872	(216,954)
Gain on settlement of accounts payable		477,372
Gain on deconsolidation			4,393,242
Interest expense		(1,771,941)	(1,803,344)
Loss on modification of line of credit		(650,000)
Loss on modification of note receivable			(1,895,434)
Debt default penalty		(286,059)
Other expense		(118,875)	(194,248)
Total other income/(expense)		(1,881,631)	283,262
NET LOSS BEFORE INCOME TAXES		(3,556,500)	(13,024,848)
Income tax expense (Note 8)		(168,527)	(86,837)
NET LOSS		$ (3,725,027)	$ (13,111,685)

Note 4 - Discontinued Operati_5

Note 4 - Discontinued Operations - Schedule of Inventory (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Raw materials	$ 86,076	$ 91,465
Work in progress	743,844	1,166,511
Finished goods	866,195	466,319
Subtotal	1,696,115	1,724,295
Allowance to reduce inventory to NRV	(6,811)	(278,456)
Total inventory, net	$ 1,689,304	$ 1,445,839

Note 4 - Discontinued Operati_6

Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total lease cost, discontinued operations	$ 572,935	$ 754,653
Total lease cost	572,935	754,653
Discontinued Operations [Member]
Finance leases - amortization of ROU assets	154,699	252,973
Finance leases - interest on lease liabilities	414,993	426,374
Operating leases	3,243	13,648
Total lease cost, discontinued operations	572,935	692,995
Total lease cost	572,935	692,995
Continuing Operations [Member] | General and Administrative Expense [Member]
Operating leases		$ 61,658

Note 4 - Discontinued Operati_7

Note 4 - Discontinued Operations - Future Minimum Lease Payments (Details) - Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]	Mar. 31, 2021USD ($)
2022	$ 544,296
2023	560,625
2024	577,444
2025	594,767
2026	612,610
Thereafter	3,168,492
Total minimum lease payments, finance leases	6,058,234
Less: Amount representing interest, finance leases	(2,525,143)
Present value of minimum lease payments, finance leases	3,533,091
Less: Current maturities of capital lease obligations, finance leases	(143,967)
Long-term capital lease obligations, finance leases	$ 3,389,124

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual)	Dec. 29, 2020USD ($)	Oct. 05, 2020USD ($)	May 07, 2020USD ($)$ / sharesshares	Oct. 23, 2017USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Aug. 10, 2020USD ($)	Jul. 24, 2020USD ($)	May 06, 2020USD ($)	Mar. 24, 2020USD ($)	Nov. 27, 2019USD ($)	Nov. 15, 2019USD ($)
Notes Payable, Current, Total					$ 3,594,804	$ 5,054,728	$ 3,594,804	$ 3,594,804
Proceeds from Lines of Credit, Total					375,000
Payments of Debt Issuance Costs					74,750	175,000
Interest Expense, Debt, Excluding Amortization						84,354
Amortization of Debt Discount (Premium)					776,122	1,150,995
Gain (Loss) on Amendment to Line of Credit					(650,000)
The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,025,000
Gain (Loss) on Amendment to Line of Credit	(650,000)
Repriced Preexisting Warrants with Convertible Debt Issuance [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares			8,002,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares			$ 0.04
Warrants and Rights Outstanding			$ 272,085								$ 49,525
Fair Value Adjustment of Warrants			$ 222,560
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity													$ 470,000
Proceeds from Lines of Credit, Total							485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased							15,000
Interest Payable					38,767		38,767	38,767
Long-term Line of Credit, Total					485,000		485,000	485,000
Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total												$ 4,000,000		$ 4,000,000
Disposal Group, Including Discontinued Operation, Consideration					4,000,000		4,000,000	4,000,000
Teco [Member] | The July 24 Note [Member]
Interest and Debt Expense, Total					12,510
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000				1,025,000		1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current	975,000
Notes Receivable, Maximum Allowed Prepayments On Note	325,000
Disposal Group, Including Discontinued Operation, Consideration	4,000,000
Gain (Loss) on Amendment to Line of Credit	$ (650,000)
Notes Receivable, Additional Advances					50,000
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage										8.00%
The July 24 Note [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity										$ 500,000
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total										$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding										3
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage				0.00%									0.00%
Debt Instrument, Face Amount				$ 700,000
Debt Instrument, Term (Year)				3 years
Debt Instrument, Present Value				$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)				20.30%
Debt Instrument, Unamortized Discount, Total				$ 178,933	0		0	0
Repayments of Debt								330,555
Notes Payable, Current, Total					369,445		369,445	369,445
Interest Expense, Debt, Total					13,929
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition									$ 190,272
Debt Instrument, Penalty Rate Waived Upon Closing of Disposition									15.00%
Convertible Debt [Member]
Interest Expense, Debt, Total					208,779
Interest Payable					228,373		$ 228,373	$ 228,373
Amortization of Debt Discount (Premium)					139,253
Convertible Debt [Member] | The 8% Note Payable dated May 7, 2020 [Member]
Debt Instrument, Interest Rate, Stated Percentage			8.00%
Debt Instrument, Face Amount			$ 150,000
Debt Instrument, Unamortized Discount, Total			150,000
Proceeds from Issuance of Long-term Debt, Net			135,000
Payments of Debt Issuance Costs			15,000
Repayments of Long-term Debt, Total			$ 8,000,000
Interest and Debt Expense, Total		$ 154,964			154,964
Interest Expense, Debt, Excluding Amortization					4,964
Amortization of Debt Discount (Premium)					$ 150,000
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License				$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of Licence				100.00%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of Licence				100.00%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Schedule of Debt Payable (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020	Apr. 23, 2019	Oct. 23, 2017
Discount, short-term notes payable	$ (296,504)	$ (608,580)
Discount, long-term notes payable	(154,590)	0
Promissory Note [Member]
Total short term notes and convertible notes payable classified as continuing operations	447,000
Discount, long-term notes payable	(154,590)
Carrying Value, long-term notes payable	292,410
Face Value, long-term notes payable	447,000
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Face Value, short-term notes payable				$ 700,000
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	197,000
Discount, long-term notes payable	(40,561)
Carrying Value, long-term notes payable	156,439
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Face Value, short-term notes payable	250,000
Discount, long-term notes payable	(114,029)
Carrying Value, long-term notes payable	135,971
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Face Value, short-term notes payable	369,445	369,445
Discount, short-term notes payable		(13,929)
Carrying Value, short-term notes payable	369,445	355,516
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Face Value, short-term notes payable	1,060,000	1,257,000
Discount, short-term notes payable		(155,340)
Carrying Value, short-term notes payable	1,060,000	1,101,660
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Face Value, short-term notes payable		2,765,000	$ 2,765,000
Discount, short-term notes payable		(29,830)
Carrying Value, short-term notes payable		2,735,170
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Face Value, short-term notes payable	325,000
Discount, short-term notes payable	(296,504)
Carrying Value, short-term notes payable	28,496
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member]
Face Value, short-term notes payable	485,000	480,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	485,000	480,000
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member]
Face Value, short-term notes payable	1,025,000
Discount, short-term notes payable
Carrying Value, short-term notes payable	1,025,000
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Face Value, short-term notes payable	1,111,863	1,271,863
Discount, short-term notes payable		(409,481)
Carrying Value, short-term notes payable	1,111,863	862,382
Promissory Note [Member]
Face Value, short-term notes payable	4,376,308	6,143,308
Discount, short-term notes payable	(296,504)	(608,580)
Carrying Value, short-term notes payable	4,079,804	5,534,728
Less: Notes payable classified as discontinued operations, face value	(485,000)	(480,000)
Less: Notes payable classified as discontinued operations, discount
Less: Notes payable classified as discontinued operations, carrying value	(485,000)	(480,000)
Total short term notes and convertible notes payable classified as continuing operations	3,891,308	5,663,308
Total short term notes and convertible notes payable classified as continuing operations	(296,504)	(608,580)
Total short term notes and convertible notes payable classified as continuing operations	3,594,804	5,054,728
Face Value, long-term notes payable	$ 3,891,308	$ 5,663,308

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)	Dec. 16, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Dec. 16, 2019USD ($)$ / sharesshares	Nov. 27, 2019USD ($)$ / shares	Nov. 18, 2019USD ($)$ / sharesshares	Oct. 30, 2019USD ($)$ / sharesshares	Oct. 23, 2019USD ($)$ / shares	Aug. 01, 2019USD ($)$ / sharesshares	Jul. 12, 2019USD ($)$ / shares	May 28, 2019USD ($)$ / sharesshares	Apr. 23, 2019USD ($)$ / shares	Feb. 28, 2019USD ($)$ / shares	Jul. 31, 2017USD ($)$ / shares	Mar. 31, 2017USD ($)$ / shares	Mar. 31, 2021USD ($)$ / sharesshares	May 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 18, 2020$ / shares	Dec. 09, 2020USD ($)	Nov. 20, 2020USD ($)	Dec. 31, 2019USD ($)
Class of Warrant or Right, Issued During Period (in shares) | shares																				43,493,809	7,622,780
Amortization of Debt Discount (Premium)																				$ 776,122	$ 1,150,995
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares																					7,583,333
Gain (Loss) on Extinguishment of Debt, Total																				467,872	$ (216,954)
Interest Expense, Debt, Excluding Amortization																					84,354
Induced Conversion of Convertible Debt Expense																					127,059
Proceeds from Convertible Debt																				725,000	2,630,000
Debt Instrument, Unamortized Discount, Current																$ 296,504		$ 296,504		296,504	608,580
Convertible Notes Payable, Noncurrent																292,410		292,410		292,410
Debt Instrument, Unamortized Discount, Noncurrent																154,590		154,590		154,590	0
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty		15.00%
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594
Litigation Settlement, Amount Final Settlement																							$ 3,006,015	$ 3,006,015
Litigation Settlement, One Time Required Payment																							25,000
Litigation Settlement, Weekly Required Payment																							$ 25,000
Litigation Settlement, Payment	$ 3,006,015
Judgment Settlement Agreement [Member] | Judicial Ruling [Member]
Litigation Settlement, Expense																				25,000
Teco [Member]
Disposal Group, Including Discontinued Operation, Consideration																4,000,000		4,000,000		4,000,000
Convertible Debt [Member]
Debt Instrument, Extended Amount																197,000		197,000		197,000
Interest Expense, Debt, Total																				208,779
Amortization of Debt Discount (Premium)																				139,253
Interest Payable																228,373		228,373		228,373
Debt Instrument, Debt Default, Amount																$ 1,060,000		$ 1,060,000		$ 1,060,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants															4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 0.60		$ 0.60
Warrants and Rights Outstanding, Term (Year)															3 years		3 years
Class of Warrant or Right, Issued (in shares) | shares																	8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																	1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants														4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																				788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares														$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)																			3 years
Class of Warrant or Right, Issued (in shares) | shares																			28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares																			1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.10		$ 0.10		$ 0.10
Warrants and Rights Outstanding, Term (Year)																3 years		3 years		3 years
Warrants and Rights Outstanding																$ 13,396		$ 13,396		$ 13,396
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total																46,886		46,886		46,886
Debt Instrument, Convertible, Beneficial Conversion Feature																				33,490
Interest Expense, Debt, Total																				28,306
Amortization of Debt Discount (Premium)																				22,412
Interest Payable																44,332		44,332		44,332
Interest Payable, Accrued Prior to Extinguishments																38,438		38,438		38,438
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage																						6.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																						$ 0.05
Debt Instrument, Unamortized Discount, Total																74,750		74,750		74,750
Debt Instrument, Convertible, Beneficial Conversion Feature																				347,000
Interest Expense, Debt, Total																				16,354
Amortization of Debt Discount (Premium)																				11,217
Convertible Notes Payable, Current																28,496		28,496		28,496
Debt Instrument, Unamortized Discount, Current																296,504		296,504		296,504
Convertible Notes Payable, Noncurrent																135,971		135,971		135,971
Debt Instrument, Unamortized Discount, Noncurrent																114,029		114,029		114,029
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																575,000		575,000		575,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																325,000		325,000		325,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount																250,000		250,000		250,000
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount																$ 425,000		$ 425,000		425,000
Proceeds from Convertible Debt																				500,250
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																				$ 543,886	829,737
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note															$ 1,000
Debt Instrument, Interest Rate, Stated Percentage															6.00%
Debt Instrument, Face Amount																	$ 2,000,000
Debt Instrument, Term (Year)																	3 years
Debt Instrument, Unamortized Discount, Total																	$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature																	904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants																	$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments															4,000		8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares															$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note														$ 1,000
Debt Instrument, Face Amount																			$ 7,201,000
Debt Instrument, Term (Year)														3 years					3 years
Debt Instrument, Unamortized Discount, Total																			$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature																			3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants																			$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments														4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares														$ 0.25
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																$ 0.10		$ 0.10		$ 0.10
Debt Instrument, Extended Amount																$ 197,000		$ 197,000		$ 197,000
Convertible Notes Payable, Total																1,257,000		1,257,000		1,257,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage												8.00%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares						$ 0.0375	$ 0.06					$ 0.17
Debt Instrument, Face Amount												$ 2,765,000									2,765,000
Debt Instrument, Unamortized Discount, Total												265,000
Interest Expense, Debt, Total																		209,292		379,956
Amortization of Debt Discount (Premium)																				29,831
Debt Conversion, Original Debt, Amount						$ 50,000	$ 75,000														125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares						1,333,333	1,250,000
Short-term Debt, Total																					2,735,170
Gain (Loss) on Extinguishment of Debt, Total																				467,872
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total												440,000
Payments for Brokerage Fees												$ 175,000
Induced Conversion of Convertible Debt Expense						$ 62,353	$ 64,706														127,059
Debt Instrument, Debt Default, Interest Rate Penalty			10.00%
Debt Instrument, Debt Default, Interest Expense			$ 9,559
Debt Instrument, Debt Default, Principal Expense			$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent			10.00%
Interest Expense, Debt, Pre-judgment Interest																				140,833
Debt Instrument, Unamortized Discount, Current																					29,830
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594																		3,264,594
Litigation Settlement, Amount Including Interest Expense																3,473,886		3,473,886		3,473,886
Promissory Note [Member]
Debt Instrument, Face Amount																4,376,308		4,376,308		4,376,308	6,143,308
Short-term Debt, Total																4,079,804		4,079,804		4,079,804	5,534,728
Debt Instrument, Unamortized Discount, Current																296,504		296,504		296,504	608,580
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage														6.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage					8.00%					8.00%			8.00%
Debt Instrument, Face Amount													$ 1,500,000
Debt Instrument, Unamortized Discount, Total				$ 57,551					$ 9,579																$ 584,842
Debt Instrument, Convertible, Beneficial Conversion Feature								$ 92,796		$ 133,806			$ 176,471
Interest Expense, Debt, Total				584,842																477,500
Amortization of Debt Discount (Premium)				57,551																409,481
Debt Conversion, Original Debt, Amount				120,000					110,000							160,000					125,000
Debt Instrument, Increase (Decrease), Net, Total				(62,449)	$ 30,000				(100,421)	100,000
Short-term Debt, Total				1,271,863	1,361,863			$ 1,269,067	$ 1,361,863	1,338,057						1,111,863		1,111,863		1,111,863					$ 687,021
Proceeds from Related Party Debt										100,000
Debt Instrument, Increase, Accrued Interest										41,863
Gain (Loss) on Extinguishment of Debt, Total					$ 0					$ (124,158)											$ (92,796)
Long-term Debt, Gross				$ 687,021
Interest Expense, Debt, Excluding Amortization																				68,019
Long Term Debt Including Interest																$ 1,256,857		$ 1,256,857		$ 1,256,857
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Unamortized Discount, Total											$ 17,225
Debt Conversion, Original Debt, Amount											170,000
Debt Instrument, Increase (Decrease), Net, Total											(152,775)
Short-term Debt, Total											$ 1,330,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent													100.00%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments													8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.04	$ 0.04			$ 0.08	$ 0.11	$ 0.11			$ 0.17			$ 0.04		$ 0.04		$ 0.04
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				3,000,000					1,000,000							4,000,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares											$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares											1,000,000

Note 7 - Property and Equipme_3

Note 7 - Property and Equipment (Details Textual) - USD ($)	Mar. 24, 2020	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Depreciation, Total			$ 34,555	$ 541,462
Depreciation, Capitalized to Inventory			532,785	$ 811,508
Teco [Member]
Sale of Stock, Percentage of Ownership	100.00%	100.00%		100.00%
Disposal Group, Including Disconitnued Operation, Estimated Future Undiscounted Cash Flows	$ 8,000,000
Disposal Group, Including Discontinued Operation, Carrying Basis	11,900,000
Disposal Group, Including Disconitnued Operation, Fair Value Disclosure	7,300,000
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down	$ 4,645,054
Disposal Group, Including Discontinued Operation, Discount Rate	17.00%
Discontinued Operations [Member]
Depreciation, Total			21,855	$ 424,501
Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down				$ 4,645,054

Note 7 - Property and Equipme_4

Note 7 - Property and Equipment - Property and Equipment (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Property and Equipment, Gross	$ 771,379
Property and Equipment, Gross, Including Discontinued Operations	6,200,097
Less accumulated depreciation and amortization	(746,357)
Less accumulated depreciation and amortization, Including Discontinued Operations	(1,298,828)
Property and Equipment, Net	25,022	$ 37,821
Property and Equipment, Net, Including Discontinued Operations	4,901,269
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations	5,428,717
Less accumulated depreciation and amortization, Discontinued Operations	(552,471)
Property and Equipment, Net, Discontinued Operations	4,876,247
Furniture and Fixtures [Member]
Property and Equipment, Gross
Property and Equipment, Gross, Including Discontinued Operations
Furniture and Fixtures [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations
Computer Equipment [Member]
Property and Equipment, Gross	151,748
Property and Equipment, Gross, Including Discontinued Operations	151,748
Computer Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations
Machinery and Equipment [Member]
Property and Equipment, Gross	619,631
Property and Equipment, Gross, Including Discontinued Operations	908,666
Machinery and Equipment [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations	289,035
Leaseholds and Leasehold Improvements [Member]
Property and Equipment, Gross
Property and Equipment, Gross, Including Discontinued Operations	3,455,600
Leaseholds and Leasehold Improvements [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations	3,455,600
Construction in Progress [Member]
Property and Equipment, Gross
Property and Equipment, Gross, Including Discontinued Operations	21,069
Construction in Progress [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations	21,069
Finance Lease Right-of-use Asset [Member]
Property and Equipment, Gross
Property and Equipment, Gross, Including Discontinued Operations	1,663,013
Finance Lease Right-of-use Asset [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Property and Equipment, Gross, Discontinued Operations	$ 1,663,013

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Effective Income Tax Rate Reconciliation, Percent, Total	(3.60%)	0.00%
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations, Total	$ 168,527	$ 86,837
Income Tax Reconciliation, Prior Year Tax Penalties	48,076
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount	486,145
Taxes Payable, Current, Total	761,509	592,982
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	154,914
Operating Loss Carryforwards, Total	51,776,062	50,596,940
Operating Loss Carryforwards, Subject to Expiration		$ 34,481,122
Operating Loss Carryforwards, Not Subject to Expiration	$ 17,294,940

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Tax benefit computed at U.S. statutory rates	$ (697,040)	$ (2,178,478)
IRC Section 280E	173,045	202,877
Other permanent items	14,407	22,948
Change in valuation allowance	26,720	1,952,653
Adjustments to valuation of deferred tax assets	603,319
Total provision for income taxes	120,451
Penalties and interest on prior year tax liabilities	48,076	86,837
Total income tax expense	$ 168,527	$ 86,837

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2020
Stock based compensation	$ 3,131,344	$ 2,943,816
Net operating loss carryforward	10,460,788	10,625,357
Impairment of long-lived assets	975,461	975,461
Depreciation and Amortization expense	(458,938)	(324,707)
Other temporary items	220,795	136,243
Total deferred tax assets	14,329,450	14,356,170
Less valuation allowance	(14,329,450)	(14,356,170)
Net deferred tax asset

Note 9 - Capital Transactions_2

Note 9 - Capital Transactions (Details Textual) - USD ($)	Jan. 02, 2021	Dec. 15, 2020	Dec. 07, 2020	Nov. 16, 2020	Dec. 16, 2019	Nov. 27, 2019	Nov. 18, 2019	Oct. 30, 2019	Aug. 01, 2019	Jul. 12, 2019	May 28, 2019	Dec. 31, 2019	Mar. 31, 2021	Jul. 11, 2019	Mar. 31, 2021	Mar. 31, 2020	Feb. 08, 2021	Jan. 01, 2021	Apr. 01, 2020	Oct. 23, 2019	Apr. 23, 2019	Mar. 31, 2019	Feb. 28, 2019
Proceeds from Warrant Exercises															$ 1,075,396	$ 1,274,790
Induced Dividend from Warrant Exercises
Class of Warrant or Right, Issued During Period (in shares)															43,493,809	7,622,780
Class of Warrant or Right, Outstanding (in shares)													85,843,036		85,843,036	84,538,161						99,790,989
Class of Warrant or Right, Expense															$ 211,000	$ 103,472
Debt Conversion, Converted Instrument, Shares Issued (in shares)																7,583,333
Induced Conversion of Convertible Debt Expense																$ 127,059
Exercise of Warrants for Stock, Shares (in shares)																17,563,000
Stock Issued During Period, Shares, Issued for Services (in shares)																2,100,000
Stock Issued During Period, Value, Issued for Services																$ 214,000
Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)															6,750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)															$ 0.045
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)													17,733,334		17,733,334	10,983,334						12,583,334
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)													$ 0.11		$ 0.11	$ 0.28						$ 0.28
Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)															3,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)															$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)													5,883,000		5,883,000	2,383,000						2,383,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)													$ 0.14		$ 0.14	$ 0.27						$ 0.27
Common Stock [Member]
Induced Dividend from Warrant Exercises
Exercise of Warrants for Stock, Shares (in shares)															35,798,809	17,563,000
Stock Issued During Period, Shares, Issued for Services (in shares)																2,100,000
Stock Issued During Period, Value, Issued for Services																$ 210
Convertible Debt [Member]
Debt Instrument, Extended Amount													$ 197,000		$ 197,000
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total													46,886		$ 46,886
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Extension Period (Year)															3 years
Debt Instrument, Extended Amount													$ 197,000		$ 197,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)													$ 0.10		$ 0.10
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Conversion, Original Debt, Amount							$ 50,000	$ 75,000								125,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)							$ 0.0375	$ 0.06													$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)							1,333,333	1,250,000
Debt Instrument, Interest Rate, Stated Percentage																					8.00%
Debt Instrument, Unamortized Discount, Total																					$ 265,000
Short-term Debt, Total																2,735,170
Induced Conversion of Convertible Debt Expense							$ 62,353	$ 64,706								127,059
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Conversion, Original Debt, Amount					$ 120,000				$ 110,000				$ 160,000			125,000
Debt Instrument, Interest Rate, Stated Percentage						8.00%				8.00%													8.00%
Debt Instrument, Unamortized Discount, Total					57,551				9,579			$ 584,842
Debt Instrument, Increase (Decrease), Net, Total					(62,449)	$ 30,000			(100,421)	$ 100,000
Short-term Debt, Total					$ 1,271,863	$ 1,361,863			$ 1,361,863	$ 1,338,057		$ 687,021	$ 1,111,863		$ 1,111,863					$ 1,269,067
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | CSW Ventures, L.P. [Member]
Debt Conversion, Original Debt, Amount											$ 170,000
Debt Instrument, Interest Rate, Stated Percentage											8.00%
Debt Instrument, Unamortized Discount, Total											$ 17,225
Debt Instrument, Increase (Decrease), Net, Total											(152,775)
Short-term Debt, Total											$ 1,330,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)					$ 0.04	$ 0.04			$ 0.11	$ 0.11			$ 0.04		$ 0.04					$ 0.08			$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)					3,000,000				1,000,000				4,000,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member] | CSW Ventures, L.P. [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)											1,000,000
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense		$ 51,050													$ 436,349	$ 287,260
Scientist and Researcher [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)															3,500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)															$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 168,000
Scientist and Researcher [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)															10 years
Former Director [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)				$ 0.03
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)				450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value				$ 4,950
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value				11,250
Share-based Payment Arrangement, Expense				$ 6,300
Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		3,250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value															$ 156,000
Share-based Payment Arrangement, Expense															62,000
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount													$ 78,000		$ 78,000
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Employees and Directors [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		33.33%
Current Employees [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		6,050,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value		$ 199,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value		$ 250,650
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercises in Period (in shares)										9,449,750		8,113,250			35,798,809
Proceeds from Warrant Exercises										$ 850,478		$ 307,249			$ 968,023
Brokerage Fees for Issuance of Common Stock and Warrants										94,498		22,566			107,373
Induced Dividend from Warrant Exercises												$ 32,215			$ 1,591,080
Class of Warrant or Right, Outstanding (in shares)														70,500,000
Class of Warrant or Right, Temporarily Reduced Exercise Price of Warrants or Rights (in dollars per share)														$ 0.10
Inducement Dividend, Exercise of Warrants										$ 230,025
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 0.03		0.65					$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 0.05		$ 0.30					$ 0.05
Convertible Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.10		$ 0.10
Class of Warrant or Right, Issued During Period (in shares)															788,000
Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year)															3 years
Warrants and Rights Outstanding													$ 13,396		$ 13,396
Employees and Director Warrants [Member] | Employees and Directors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)			$ 0.04
Warrants and Rights Outstanding			$ 133,000
Share-based Payment Arrangement, Expense			$ 133,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			3,500,000
Warrants and Rights Outstanding, Term (Year)			10 years
Compensation Warrants Issued to Brokers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.01
Warrants and Rights Outstanding	$ 367,196																	$ 135,861
Class of Warrant or Right, Outstanding (in shares)	9,424,613
Class of Warrant or Right, Expense	$ 231,335
Compensation Warrants Issued to Brokers [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 0.25
Compensation Warrants Issued to Brokers [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																		$ 1
Replacement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)																	$ 0.10
Warrants and Rights Outstanding																	$ 1,182,920
Warrants and Rights Outstanding, Term (Year)																	3 years
Class of Warrant or Right, Outstanding (in shares)																	42,705,809
Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)													85,843,036		85,843,036
Warrants [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.01		$ 0.01
Warrants [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.90		$ 0.90

Note 9 - Capital Transactions -

Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Outstanding (in shares)	84,538,161	99,790,989
Warrants issued (in shares)	43,493,809	7,622,780
Warrants issued, exercise price (in dollars per share)	$ 0.10	$ 0.30
Warrants exercised (in shares)	(35,798,809)	(17,563,000)
Warrants expired/cancelled (in shares)	(6,390,125)	(5,312,608)
Outstanding (in shares)	85,843,036	84,538,161
Minimum [Member]
Warrants exercised, exercise price (in dollars per share)	$ 0.03	$ 0.035
Warrants expired/cancelled, exercise price (in dollars per share)	0.60	0.50
Maximum [Member]
Warrants exercised, exercise price (in dollars per share)	0.035	0.10
Warrants expired/cancelled, exercise price (in dollars per share)	$ 0.90	$ 2

Note 10 - Employee Benefit Pl_3

Note 10 - Employee Benefit Plan (Details Textual) - USD ($)	Dec. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Oct. 25, 2018	Jun. 30, 2015	Feb. 06, 2008
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		2,022,443
Class of Warrant or Right, Expense		$ 211,000	$ 103,472
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 78,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0	0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense		$ 0	$ 0
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 51,050	$ 436,349	$ 287,260
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						4,500,000
The 2014 Equity Compensation Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)					8,500,000
GB Sciences, Inc 2018 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)				10,000,000

Note 10 - Employee Benefit Pl_4

Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2021
Weighted-average volatility	127.00%
Expected term (in years) (Year)	10 years
Risk-free interest rate	0.93%

Note 10 - Employee Benefit Pl_5

Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Employee [Member]
Outstanding, options (in shares)	10,983,334	12,583,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.28	$ 0.28
Outstanding, weighted average remaining contractual life (Year)	6 years 292 days	6 years 7 days	7 years 65 days
Outstanding, aggregate intrinsic value	$ 172,000		$ 43,000
Granted, options (in shares)	6,750,000
Granted, weighted average exercise price (in dollars per share)	$ 0.045
Exercised, options (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)		(1,600,000)
Forfeited, weighted average exercise price (in dollars per share)		$ 0.27
Outstanding, options (in shares)	17,733,334	10,983,334	12,583,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.28	$ 0.28
Fully vested and expected to vest, options (in shares)	17,733,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.11
Exercisable, options (in shares)	15,566,668
Exercisable, weighted average exercise price (in dollars per share)	$ 0.12
Share-based Payment Arrangement, Nonemployee [Member]
Outstanding, options (in shares)	2,383,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.27	$ 0.27
Outstanding, weighted average remaining contractual life (Year)	8 years 40 days	6 years 273 days	7 years 277 days
Outstanding, aggregate intrinsic value	$ 35,000		$ 492,250
Granted, options (in shares)	3,500,000
Granted, weighted average exercise price (in dollars per share)	$ 0.05
Exercised, options (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)
Forfeited, weighted average exercise price (in dollars per share)
Outstanding, options (in shares)	5,883,000	2,383,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.14	$ 0.27	$ 0.27
Fully vested and expected to vest, options (in shares)	5,883,000
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.14
Exercisable, options (in shares)	5,883,000
Exercisable, weighted average exercise price (in dollars per share)	$ 0.14

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	Dec. 16, 2020USD ($)	Sep. 17, 2020USD ($)	Aug. 24, 2020USD ($)	Jul. 14, 2020USD ($)	Apr. 22, 2020USD ($)	Sep. 18, 2017USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)
Research and Development Expense, Total							$ 352,274	$ 1,543,397
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party				$ 3,264,594
Litigation Settlement, Payment	$ 3,006,015
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					$ 73,050
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member]
Payments for Legal Settlements		$ 25,000
Reduction in Cost Basis of Fixed Asset Related to Litigation		$ 48,050
Agreement With Louisiana State University AgCenter [Member]
Term of Agreement (Year)						5 years	3 years
Option to Renew Agreement, Amount						2
Term of Agreement, Renewal (Year)						5 years
Research and Development Expense, Total						$ 500,000	$ 250,000		$ 750,000
Annual Research Contributions			$ 250,000

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)	Jan. 02, 2021	Nov. 16, 2020	Mar. 31, 2021	Mar. 31, 2020
Notes Payable, Related Parties, Current				$ 151,923
Leslie Bocskor [Member]
Due to Related Parties, Total		$ 78,245
Payments for Postemployment Benefits		6,500
Salary and Wage, Excluding Cost of Good and Service Sold, Total			44,192	$ 40,192
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member]
Related Party Transaction, Expenses from Transactions with Related Party		20,000
Related Party Transaction, Amounts of Transaction		$ 84,745
Ksenia Griswold [Member] | Unpaid Severance Compensation [Member]
Due to Related Parties, Total	$ 114,159
Related Party Transaction, Amounts of Transaction	57,000
Other Income	$ 57,159
John Davis [Member]
Notes Payable, Related Parties, Current			151,923
Officers and Directors [Member]
Due to Related Parties, Total			$ 84,913

Note 13 - Sale of 50% Members_3

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC (Details Textual) - USD ($)	Dec. 16, 2020	Dec. 08, 2020	Oct. 29, 2020	Nov. 15, 2019	Sep. 30, 2020	Aug. 31, 2020	Oct. 15, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Aug. 24, 2020	Aug. 23, 2020
Receivable with Imputed Interest, Discount				$ 1,389,408
Deconsolidation, Gain (Loss), Amount				4,393,242						$ 4,393,242
Repayments of Related Party Debt									$ 151,923
Wellcana Note [Member]
Note Receivable, Interest Rate									5.00%
Receivable with Imputed Interest, Discount									$ 1,389,408
Receivable with Imputed Interest, Effective Yield (Interest Rate)									17.00%
Receivable with Imputed Interest, Net Amount, Total				6,610,592					$ 6,610,592
Proceeds from Collection of Notes Receivable	$ 4,900,000							$ 4,900,000
Financing Receivable, after Allowance for Credit Loss, Total										$ 7,119,857
GB Sciences Louisiana, LLC [Member]
Deconsolidation, Gain (Loss), Amount				4,393,242
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC [Member]
Proceeds from Divestiture of Businesses				8,000,000
Earnout Payments				$ 8,000,000
Proceeds from Collection of Notes Receivable and Liabilities Forgiveness							$ 5,224,423
Repayments of Related Party Debt						$ 151,923	151,923
Debt Instrument, Decrease, Forgiveness					$ 172,500		172,500
Proceeds from Collection of Notes Receivable	$ 4,150,000				$ 550,000	$ 550,000	4,900,000
Note Receivable Satisfied							8,000,000
Annual Research Contribution Commitment to LSU Assumed by Counter Party							250,000
Notes Receivable, Net, Scheduled Payments												$ 500,000	$ 750,000
Financing Receivable, after Allowance for Credit Loss, Total											$ 4,350,000
Notes Receivable, Not Yet Collectible							$ 4,350,000	$ 4,350,000
Notes Receivable, Due Date Extended		$ 4,350,000
Notes Receivable, Amount for Which Proof of Funds is Required		4,350,000
Notes Receivable, Escrow Deposit Required of Other Party		250,000
Notes Receivable, Escrow Payment Received			$ 250,000
Notes Receivable, Escrow Payment Not Yet Received		250,000
Notes Receivable, Retained Amount Not Offset Against Full Balance		$ 50,000
Wellcana Group, LLC [Member] | GB Sciences Louisiana, LLC, Sale of Equity [Member]
Sale of Stock, Percentage of Ownership				50.01%

Note 13 - Sale of 50% Members_4

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Note Receivable (Details) - USD ($)	Mar. 31, 2021	Nov. 15, 2019
Total proceeds		$ 8,000,000
Discount on note receivable		(1,389,408)
Wellcana Note [Member]
June 1, 2020		500,000
September 1, 2020		750,000
December 1, 2020		1,000,000
March 1, 2020		1,250,000
June 1, 2021		1,500,000
September 1, 2021		1,500,000
December 1, 2021		1,500,000
Discount on note receivable	$ (1,389,408)
Net present value	$ 6,610,592	$ 6,610,592

Note 13 - Sale of 50% Members_5

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Deconsolidation (Details) - USD ($)	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Gain on deconsolidation	$ 4,393,242		$ 4,393,242
GB Sciences Louisiana, LLC [Member]
Present value of promissory note	6,610,592
Carrying amount of non-controlling interest	8,707,651
Total	15,318,243
Carrying amount of assets	14,715,798
Carrying amount of liabilities	(3,790,797)
Net assets deconsolidated	$ 10,925,001

Note 13 - Sale of 50% Members_6

Note 13 - Sale of 50% Membership Interest in GB Sciences Louisiana, LLC - Loss on Modification of Notes Receivable (Details) - USD ($)	Dec. 16, 2020	Oct. 15, 2020	Mar. 31, 2021	Mar. 31, 2020
Loss on modification of note receivable				$ (1,895,434)
Wellcana Note [Member]
Total cash payments to be made by October 15, 2020	$ 4,900,000	$ 4,900,000
Liabilities to be forgiven upon receipt of October 15, 2020 payment		324,423
Total receivable (as modified)		$ 5,224,423
Carrying value of note receivable as of March 31, 2020				6,969,720
Accrued interest as of March 31, 2020				150,137
Total amount receivable (prior to modification)				$ 7,119,857

Note 14 - Sale of 100% Member_2

Note 14 - Sale of 100% Membership Interests in Nevada Subsidiaries (Details Textual)	Dec. 29, 2020USD ($)	Mar. 24, 2020USD ($)	Nov. 27, 2019USD ($)	Nov. 15, 2019USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Jul. 24, 2020USD ($)	Oct. 23, 2017
Proceeds from Lines of Credit, Total						$ 375,000
Gain (Loss) on Amendment to Line of Credit						(650,000)
Proceeds from Sale and Collection of Notes Receivable, Total						5,051,923
The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total	$ 1,025,000
Gain (Loss) on Amendment to Line of Credit	(650,000)
Teco [Member]
Management Fees Accrued					$ 850,000	850,000		$ 850,000
Proceeds from Sale and Collection of Notes Receivable, Total						$ 4,000,000
Notes Receivable Term (Year)						3 years
Teco [Member]
Sale of Stock, Percentage of Ownership		100.00%		100.00%			100.00%
Proceeds from Divestiture of Businesses		$ 4,000,000		$ 4,000,000
Financing Receivable, after Allowance for Credit Loss, Total		$ 4,000,000		$ 4,000,000
Notes Receivable, Interest Rate		8.00%		8.00%
Notes Receivable, Term of Monthly Installments (Month)		3 years
Teco [Member] | July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000
Increase (Decrease) in Notes Receivable, Current	(975,000)
Note Receivable, Maximum Allowed Prepayments On Note	325,000
Teco [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000				1,025,000	$ 1,025,000		1,025,000
Increase (Decrease) in Notes Receivable, Current	975,000
Gain (Loss) on Amendment to Line of Credit	$ (650,000)
Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 470,000
Proceeds from Lines of Credit, Total								$ 485,000
Teco Note [Member] | Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 470,000
The July 24 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
The July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total									$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding									3
The July 24 Note [Member] | Secured Debt [Member] | AJE Management, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.00%
Proceeds from Lines of Credit, Total					$ 375,000
July 24 Note [Member] | Teco [Member]
Financing Receivable, after Allowance for Credit Loss, Total									$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding									3
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Debt Instrument, Interest Rate, Stated Percentage			0.00%							0.00%
Teco [Member]
Sale of Stock, Percentage of Ownership				75.00%
Sale of Stock, Consideration Received on Transaction				$ 3,000,000
Sale of Stock, Additional Earn-out Payments				$ 3,000,000
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership			100.00%
Sale of Stock, Consideration Received on Transaction			$ 300,000
GB Sciences Nopah, LLC [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Sale of Stock, Consideration to Be Received By Means of Debt Reduction			$ 300,000

Note 15 - Concentrations (Detai

Note 15 - Concentrations (Details Textual)	12 Months Ended
	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Cash, Uninsured Amount	$ 513,901
Revenues, Total
NEVADA
Revenues, Total		3,120,620
LOUISIANA
Revenues, Total		$ 569,077
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Customers	3	2
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk, Percentage	18.40%	26.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Two [Member]
Concentration Risk, Percentage	16.70%	13.00%
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Customer Three [Member]
Concentration Risk, Percentage	13.30%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | NEVADA
Concentration Risk, Percentage		85.00%
Geographic Concentration Risk [Member] | Revenue Benchmark [Member] | LOUISIANA
Concentration Risk, Percentage		15.00%

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Jun. 14, 2021	May 11, 2021	Mar. 24, 2020	Nov. 15, 2019	Mar. 31, 2021	Mar. 31, 2020
Class of Warrant or Right, Exercised During Period (in shares)					35,798,809	17,563,000
Proceeds from Warrant Exercises					$ 1,075,396	$ 1,274,790
Subsequent Event [Member]
Class of Warrant or Right, Exercised During Period (in shares)	1,672,000
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 0.03
Proceeds from Warrant Exercises	$ 50,160
Teco [Member]
Proceeds from Divestiture of Businesses			$ 4,000,000	$ 4,000,000
Teco [Member] | Subsequent Event [Member]
Proceeds from Divestiture of Businesses		$ 200,000